Womb Stem Cell Therapy Reverses Brain Issues in Spina Bifida Babies
In a medical breakthrough, stem cell therapy performed on babies while still in the womb has been shown to reverse brain abnormalities linked to the severe birth defect spina bifida. Experts are now optimistic that this pioneering procedure could fundamentally alter the lifelong health trajectories of those born with the condition.
Understanding Spina Bifida and Its Impact
Spina bifida occurs when a baby's spine fails to develop fully during pregnancy, typically diagnosed either prenatally or shortly after birth. There are two primary types: open spina bifida and closed spina bifida. The open form, known as myelomeningocele or meningocele, is less common but more serious, causing the spinal cord to protrude through a gap in the spine.
Symptoms can be severe and lifelong, including:
- Walking difficulties or paralysis
- Incontinence
- Loss of sensation in the legs
- A curved spine
- Fluid buildup in the brain, potentially leading to learning difficulties
While fetal surgery to close open spina bifida has been available, researchers note it "does not fully address" mobility problems that arise from damage to lower motor neurons, which connect the brainstem and spinal cord to skeletal muscles.
The Groundbreaking Clinical Trial
The landmark trial, conducted in California and published in The Lancet, involved six pregnant women between 24 and 25 weeks gestation. All their babies had been diagnosed with myelomeningocele and exhibited hindbrain herniation, a brain abnormality associated with spina bifida.
Each patient underwent fetal surgery to correct the spinal defect. In an innovative additional step, surgeons applied stem cells derived from donated placentas directly to the exposed spinal cord of the fetus. This combined approach marked a significant advancement in prenatal care.
The six babies were delivered between July 2021 and December 2022. Remarkably, all were born with successful spinal repairs intact, showing no signs of infection or abnormal tissue growth. Post-birth MRI scans confirmed that the hindbrain herniation had been completely reversed.
Potential for Lifelong Health Transformation
Researchers heralded the study as establishing "a scalable and clinically feasible platform for the targeted delivery of biological therapeutics to the fetus." They emphasized that integrating cell-based therapy into fetal surgery under stringent regulatory oversight demonstrates both feasibility and safety.
By intervening at early developmental stages, this approach has the potential to alter lifelong health trajectories, reducing the burden of chronic disability and minimizing the long-term social and economic impact of these conditions, the researchers stated.
The six children from the trial are receiving routine care but will be followed up until age six to assess the long-term safety of the treatment. Encouraged by these phase one results, experts have now enrolled 35 patients in a subsequent study to further validate the findings.
Broader Implications and Prevalence
Spina bifida affects approximately one in 1,000 births annually in the United Kingdom, making this research particularly significant for public health. The successful reversal of brain abnormalities through prenatal stem cell therapy offers new hope for families facing this diagnosis, potentially reducing the severity of symptoms that have traditionally required extensive medical management throughout life.
This innovative treatment represents a convergence of advanced surgical techniques and regenerative medicine, pointing toward a future where birth defects might be corrected before a child even enters the world.
